重组人血管内皮抑制素靶向治疗联合DP化疗在晚期非小细胞肺癌患者中的效果研究  

Effect of recombinant human endostatin targeting therapy combined with DP chemotherapy on advanced non-small cell lung cancer

作　　者：李兴[1] 马丽娜[2] 王美清[1] 崔荣龙 

机构地区：[1]中南大学湘雅医学院附属海口医院/海南省海口市人民医院肿瘤化疗科,570208 [2]中南大学湘雅医学院附属海口医院/海南省海口市人民医院神经内科,570208

出　　处：《检验医学与临床》2017年第23期3492-3494,共3页Laboratory Medicine and Clinic

摘　　要：目的评价重组人血管内皮抑制素靶向治疗联合DP化疗在晚期非小细胞肺癌患者中的效果。方法选取68例晚期非小细胞肺癌患者采用奇偶法分为试验组和对照组。对照组给予常规DP化疗(多西他赛+顺铂),试验组在对照组基础上行重组人血管内皮抑制素靶向治疗,对比两组临床疗效、CT灌注成像参数及不良反应情况,并对两组患者生存率进行分析。结果试验组和对照组临床疗效比较差异有统计学意义(P<0.05),且试验组总缓解率高于对照组(P<0.05);试验组CT灌注成像参数血流量(BF)、血容量(BV)和表面通透性(PS)显著低于对照组,而对比剂平均通过时间(MTT)显著高于对照组,两组间各项参数比较差异均有统计学意义(P<0.05);试验组患者无进展生存期及1年累计生存率均明显高于对照组(P<0.05);两组不良反应发生率比较差异无统计学意义(P>0.05)。结论重组人血管内皮抑制素靶向治疗联合DP化疗可以有效改善晚期非小细胞肺癌近期疗效和远期生存率,CT灌注成像能够有效评估肺癌患者治疗效果,值得推广应用。Objective To evaluate the curative effect of recombinant human endostatin targeting therapy combined with DP chemotherapy on advanced non-small cell lung cancer.Methods Sixty-eight cases of patients with advanced non-small cell lung cancer were selected and divided into experimental group and control group by the parity method.The control group were treated with DP chemotherapy,while the experimental group were treated with targeted therapy of recombinant human endostatin based on the control group.The clinical treatment effect,indexes of CT perfusion imaging,survival rates after 6 months,12 months,24 months of following-up and adverse reactions were compared between the two groups.Results The difference in the clinical treatment effect was statistically significant between the two groups（P〈0.05）,and the total remission rate in the experimental group was significantly higher than that in the control group（P〈0.05）.The blood flow（BF）,blood volume（BV）and permeability surface（PS）levels in the experimental group were significantly lower than those in the control group,while the mean transit time（MTT）level was higher than that in the control group,and the differences in the indexes between the two groups were statistical significance（P〈0.05）.Progression free survival and a year cumulative survival rates in the experimental group were significantly higher than those in the control group（P〈0.05）.The differences in the incidence rates and grade distribution of adverse reactions between the two groups were not statistically significant（P〈0.05）.Conclusion Targeted therapy of recombinant human endostatin combined with DP chemotherapy in advanced non-small cell lung cancer could effectively improve the short-term effect and long-term survival rate,which is worthy of promotion and application.

关 键 词：重组人血管内皮抑制素 靶向治疗 DP化疗 非小细胞肺癌 CT灌注成像 

分 类 号：R446.5[医药卫生—诊断学]